Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
5 May 2017
E-003172-17
Question for written answer
to the Commission
Rule 130
Mireille D'Ornano (ENF)

 Subject:  Termination of the lease at the European Medicines Agency
 Answer(s) 

Because the European Medicines Agency did not include a termination clause in the lease contract for its premises in London, the EU will have to continue paying until 2039, in principle even if the EMA does not remain in London after Brexit. It is expected to cost EUR 347.6 million.

1. Has the Commission included a termination clause in the lease contracts for all the properties it rents (including the Information Offices)?

2. Why did the EMA fail to include such a clause? Brexit may well have been hard to foresee, but other unexpected events can happen during a period of 30 years.

3. What is the situation in respect of the EU agencies in this regard?

Original language of question: FR 
Last updated: 17 May 2017Legal notice